Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation

• Published in: BMC anesthesiology Vol. 21; no. 1; p. 33
• Main Authors: Zhou, Zhen-Feng, Zhai, Wen, Yu, Li-Na, Sun, Kai, Sun, Li-Hong, Xing, Xiu-Fang, Yan, Min
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.02.2021; BioMed Central; BMC
• Subjects: Acids; Adults; Antifibrinolytic agents; Blood; Cardiac patients; Cardiac surger; Comparative analysis; Coronary artery bypass; Dosage; Endocarditis; Fibrinolysis; Heart; Heart surgery; Investigations; Medical examination; Normal distribution; Placebos; Plasma levels; Plasmin; Plasminogen activator inhibitors; Protamine sulfate; Proteins; Surgery; t-Plasminogen activator; Thrombin; Thrombomodulin; Tissue plasminogen activator; Tranexamic acid; Variance analysis; Womens health; Tranexamic acid; Tissue plasminogen activator; Fibrinolysis; Cardiac surger
• ISSN: 1471-2253; 1471-2253
• DOI: 10.1186/s12871-021-01234-8

The blood saving efficacy of TXA in cardiac surgery has been proved in several studies, but TXA dosing regimens were varied in those studies. Therefore, we performed this study to investigate if there is a dose dependent in-vivo effect of TXA on fibrinolysis parameters by measurement of fibrinolysis markers in adults undergoing cardiac surgery with CPB. A double-blind, randomized, controlled prospective trial was conducted from February 11, 2017 to May 05, 2017. Thirty patients undergoing cardiac valve surgery were identified and randomly divided into a placebo group, low-dose group and high-dose group by 1: 1: 1. Fibrinolysis parameters were measured by plasma levels of D-Dimers, plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), plasmin-antiplasmin complex (PAP), tissue plasminogen activator (tPA) and thrombomodulin (TM). Those proteins were measured at five different sample times: preoperatively before the TXA injection (T ), 5 min after the TXA bolus (T ), 5 min after the initiation of CPB (T ), 5 min before the end of CPB (T ) and 5 min after the protamine administration (T ). A Thrombelastography (TEG) and standard coagulation test were also performed. Compared with the control group, the level of the D-Dimers decreased in the low-dose and high-dose groups when the patients arrived at the ICU and on the first postoperative morning. Over time, the concentrations of PAI-1, TAFI, and TM, but not PAP and tPA, showed significant differences between the three groups (P <  0.05). Compared with the placebo group, the plasma concentrations of PAI-1 and TAFI decreased significantly at the T3 and T4 (P <  0.05); TAFI concentrations also decreased at the T5 in low-dose group (P < 0.05). Compared with the low-dose group, the concentration of TM increased significantly at the T4 in high-dose group. The in-vivo effect of low dose TXA is equivalent to high dose TXA on fibrinolysis parameters in adults with a low bleeding risk undergoing valvular cardiac surgery with cardiopulmonary bypass, and a low dose TXA regimen might be equivalent to high dose TXA for those patients. ChiCTR-IPR-17010303 , Principal investigator: Zhen-feng ZHOU, Date of registration: January 1, 2017.